Jan 2002 EDMA The central role of the Medical Laboratory in a World of Managed Health An EDMA presentation of the benefits of in vitro testing as a basis.

Slides:



Advertisements
Similar presentations
Nursing Diagnosis: Definition
Advertisements

PERSONALIZED MEDICINE: Planning for the Future You, Your Biomarkers and Your Rights.
429 pharmaceutical care Plan Refa’a AlAjmi. Goal of therpay A goal of therapy is the desired response or endpoint that you and your patient want to achieve.
Disease State Management The Pharmacist’s Role
Cap.org v. # Pathologists’ Role in Coordinated Care and Managing Patient Populations.
“Rational Pharmacology” and Health Economics By Alan Maynard.
Reimbursement Getting Paid for What You Do. Enhancing Reimbursement: What do You Need to Know? Types of health plans and differences Authorization process.
ECONOMIC ASSESSMENT OF IMPLEMENTATION TREATMENT GUIDELINES OF HYPERTENSION IN OUT-PATIENT PRACTICE Kulmagambetov IR Karaganda State Medical Academy, Kazakhstan.
Drug Utilization Review (DUR)
TRAINING FOR ANTIMICROBIAL STEWARDSHIP PROGRAMMES IN HOSPITALS JUNE 2014.
Scope of Nursing Lecturer/ Hanaa Eisa Rawhia Salah
Genetic Testing in Genomic Medicine Gail H. Vance M.D. Professor, Department of Medical & Molecular Genetics Indiana University School of Medicine.
1.03 Healthcare Trends.
1 Drug and Therapeutics Committee Session 10. Standard Treatment Guidelines.
Personal and Consumer Health 1. Objectives 1.Demonstrate the ability to access and describe health information, health products, and health services in.
CE2012 – Thursday 20 September The In Vitro Diagnostics View Doris-Ann Williams Chief Executive, BIVDA CC Celebrating 20 years representing the IVD industry.
Screening and Early Detection Epidemiological Basis for Disease Control – Fall 2001 Joel L. Weissfeld, M.D. M.P.H.
Component 1: Introduction to Health Care and Public Health in the U.S. 1.5: Unit 5: Financing Health Care (Part 2) 1.5d: Controlling Medical Expenses.
Genomics Alexandra Hayes. Genomics is the study of all the genes in a person, as well as the interactions of those genes with each other and a person’s.
Clinical Unit of Health Promotion WHO Collaborating Centre for Evidence-Based Health Promotion in Hospitals Quality tools and Health Promotion Implementation.
“Put the Power of Predictive Analytics in the Hands of Clinical Researchers” Filippos Katsampouris Marketing Manager Healthcare & Pharmaceutical Accounts.
Introduction To Pharmacy Practice
The Business Case for Bidirectional Integrated Care: Mental Health and Substance Use Services in Primary Care Settings and Primary Care Services in Specialty.
1.03 Healthcare Trends Understand healthcare agencies, finances, and trends Healthcare Trends Technology Epidemiology Geriatric Care Wellness Cost.
Al H 116/Rad T 216 Financial Aspects of Hospital Management.
Why are we learning this? How scientific knowledge (pharmacology, therapeutics) and clinical skills (measuring blood pressure, glucoses, drug information)
IMPROVING DIABETES MANAGEMENT IN PRIMARY CARE
Healthcare Reform The “Affordable Care Act” How Will It Affect Substance Abuse Care?
Basma Y. Kentab MSc.. 1. Define ambulatory care 2. Describe the value of ambulatory care practices 3. Explore pharmacy services in some ambulatory care.
16 February, 2003medXchange© 2003 Private & Confidential 1 INTEGRATED ELECTRONIC MEDICAL RECORD IEMR AND MEDICAL KNOWLEDGE BASE.
The Value of Medication Therapy Management Services.
Point of Care testing (POCT) For Sexually Transmitted Infections (STI) Barbara Bewley Operations Manager Pathology Clinical Services.
Richardia Gibbs-Hook Julie Walker.  Patient satisfaction surveys are one tool by which quality and safety are measured. ◦ Hospital Consumer Assessment.
PERIODIC MEDICAL EXAMINATION BY DR. ANGELA ESOIMEME MBBS, MPH, FWACGP.
Social Pharmacy Lecture no. 6 Rational use of drugs Dr. Padma GM Rao
Public Health Preventive Medicine and Epidemiology Prof. Ashry Gad Mohammed MB, ChB. MPH, Dr P.H Prof. of Epidemiology College of Medicine King Saud University.
21/4/2008 Evaluation of control measures 1. 21/4/2008 Evaluation of control measures 2 Family and Community Medicine Department.
NPS MEDICINEWISE Lynn Weekes Chief Executive.
Fiscal Planning (Budgeting). Fiscal Planning Fiscal planning is not intuitive; it is a learned skill that improves with practice. Fiscal planning requires.
بسم الله الرحمن الرحيم جامعة أم درمان الإسلامية كلية الطب و العلوم الصحية - قسم طب المجتمع مساق البحث العلمي / الدفعة 21 Basics of Clinical Trials.
Broadband & Healthcare Jason Crosby Strategic Healthcare Partners.
Quality Education for a Healthier Scotland Pharmacy Pharmaceutical Care Planning Vocational Training Scheme: Level = Stage 2 Arlene Shaw Specialist Clinical.
Barcode Technology in healthcare Nowadays, published reports illustrate high rates of medical error (adverse events) and the increasing costs of healthcare.
Transforming Maryland’s Health Care & Engaging Communities Charles County Forum on Maryland’s All Payer System Transformation Carmela Coyle President &
Introduction.
Unit 15: Screening. Unit 15 Learning Objectives: 1.Understand the role of screening in the secondary prevention of disease. 2.Recognize the characteristics.
EUROPEAN INSTITUTE OF MEDICINE E O M European Academy of Sciences and Arts Health is Wealth Strategic Visions for European Healthcare at the Beginning.
1 Trends in Health Care Changes in health care –Many events lead to changes in health care –Changes in health care are inevitable and occur rapidly –Health.
SCREENING FOR DISEASE. Learning Objectives Definition of screening; Principles of Screening.
Health Care in Australia Medicare and Private Health Insurance.
Presentation Developed for the Academy of Managed Care Pharmacy
بسم الله الرحمن الرحيم Community Medicine Lec -11-
 Pharmaceutical Care is a patient-centered, outcomes oriented pharmacy practice that requires the pharmacist to work in concert with the patient and.
Screening Tests: A Review. Learning Objectives: 1.Understand the role of screening in the secondary prevention of disease. 2.Recognize the characteristics.
European Patients’ Academy on Therapeutic Innovation Challenges in Personalised Medicine.
Moiz Bakhiet, MD, PhD, Professor and Chairman
Medication therapy management
Hereditary Cancer Predisposition: Updates in Genetic Testing
Antibiotics: handle with care!
1st International Online BioMedical Conference (IOBMC 2015)
1.03 PP3 Healthcare Trends.
1.03 Healthcare Trends.
1.03 Healthcare Trends.
1.03 Healthcare Trends.
Diagnosis of disease M2/D2
What is Patient Blood Management?
Thank you to the Congressional Public Health Caucus, which has brought us today to talk about an important issue that affects patient care and treatment,
1.03 Healthcare Trends.
1.03 Healthcare Trends.
1.03 Healthcare Trends.
Presentation transcript:

Jan 2002 EDMA The central role of the Medical Laboratory in a World of Managed Health An EDMA presentation of the benefits of in vitro testing as a basis for better decisions in health care

Jan 2002 EDMA In Vitro Testing: Health Information Technology u Medical Laboratory testing is highly automated and provides increasing quantities of valuable data at low cost. u The information about health that this data provides is a basis for better decision-making in health care < by medical professions in management of trauma and disease < by individuals for evaluation and maintenance of their own health < by health economists to assess the value of medical interventions u However, medical professions are often poorly informed about advances in in vitro testing and opportunities to improve health are lost u The public is becoming aware of health care interventions and the value of in vitro testing, via media stories and increasingly via the Internet u This will inevitably lead to changes in the way health care is delivered For better decisions in health care

Jan 2002 EDMA Risk by Chance Risk by Choice Genetics, trauma Diet, lifestyle Collective responsibility Individual responsibility Insurable collectively Still insurable collectively Disease Management Health Management “Patients” “People” Medical responsibility Personal responsibility Collective Individual u Choices imply responsibility as well as freedom u Individual choices can greatly increase risk of disease u Better individual choices lead to better health Why do we need health care? Risk and Responsibility for Health Better individual health management now will reduce the need for medical intervention later

Jan 2002 EDMA Screening and Prevention u Screening targeted populations for disease risk u Providing information about predisposition to disease / genetic testing u Preventing spread of infection, e.g. via the blood supply u Ensuring continued health and avoiding disease as part of individual responsibility for health In vitro testing : an investment in health care

Jan 2002 EDMA Diagnosis, the key to effective treatment u Early and correct diagnosis is the key to effective treatment < Late diagnosis : possibly ineffective treatment of advanced disease < Incorrect diagnosis : incorrect treatment u Family Practitioner is the diagnostic gatekeeper for treatment < not aware of the wide range of very sensitive & specific tests < not able to use the results to full advantage u Patients / public beginning to learn from Internet < Patients are interested in early and correct diagnosis < The “impatient” patient u Normal results eliminate doubt, rule out unnecessary interventions, provide reassurance Early and correct diagnosis ensures that subsequent treatment is appropriate and effective

Jan 2002 EDMA u Evaluating patient’s condition during treatment u Reassessment and update of treatment u Monitoring and managing treatment (theranostics), for example < self-testing in diabetes < determining susceptibility to antibiotics < therapeutic drug monitoring in immunosuppression u Objective information for Evidence Based Medicine u Genomic pharmaceuticals (drugs tailored for the individual) u Rehabilitation and wellness testing Therapy & Rehabilitation Laboratory testing provides objective information in evaluating the effects of treatment and a return to health

Jan 2002 EDMA In Vitro Testing: An enabling technology u Advanced technologies < antibody-based immunoassays, fluorescent markers < nucleic acid probes, genetics < surface nano-techniques (diagnostic chips) u In vitro testing is an enabling technology < allows self testing and individual responsibility for health < can provide genetic data about disease risk factors < is the basis of genomic drug therapy, pharmaceuticals tailored to the individual and patient selection for drug therapy. < provides objective information for evidence based medicine u Reimbursement systems must become adaptable and flexible to support health management and the adoption of this enabling technology

Jan 2002 EDMA In Vitro Testing: Providing evidence for medical interventions u Evidence Based Medicine < Resource allocation in health care increasingly requires evidence of effectiveness / benefit < Increased use of laboratory testing will provide the objective evidence that is needed to assess medical treatments u Evidence based in vitro testing < In vitro test results provide information as a basis for better medical decision making. Most tests provide incremental information in a wide variety of clinical situations: difficult to measure the value of a single test result in a given clinical situation. Section B includes examples of benefits of in vitro testing In vitro testing : for better decisions in health care

Jan 2002 EDMA In Vitro Testing: Cost-effective to test more u In vitro tests < 1% of total health care costs < increased testing cannot significantly increase costs of health care < increased testing will allow earlier and more correct treatment, decreasing the costs of health care long term u Personnel costs are the dominant expense in health care < consultation time : expensive for doctor and patient < automated laboratories : cost / test decreased 50 % in 10 years u A possible future for in vitro testing < self ordering of tests - individual awareness < multi-parameter tests done on small sample (diagnostic chip) < results available and commented on by “Internet Consultant” < individual consults with peers and family < first visit to family physician if needed u Reimbursement systems out of phase with possible developments

Jan 2002 EDMA In Vitro Testing: Benefits u EDMA approach < Does the treatment or intervention benefit the patient? < Does it have a clinical benefit? < If so, is it affordable and who should pay for it? u To view EDMA’s presentation on the benefits of in vitro testing, including examples click here u In vitro testing provides: < patient benefits < clinical benefits and < economic benefits The basis for better decisions in health care

Jan 2002 EDMA Contribution to Individual/Patient satisfaction u Providing information u Enabling self treatment u Preventing infections u Avoiding unnecessary, painful or invasive treatment u Avoiding relapses, delaying complications u Getting better faster u Reducing hospital stay, reducing family disruption Meeting consumer expectations In vitro testing provides objective information when assessing treatment Positive effect of normal results u for individuals - confirming health u for doctors - removing doubts

Jan 2002 EDMA Clinical contribution u Valid, quantified information in a simple format u Vital component in evaluation of treatment u Definitive diagnosis / appropriate treatment u Reduction of morbidity u Risk prediction and reduction u Improved compliance u Monitors / quantifies therapy u Scientific basis for therapy and rehabilitation The medical laboratory is an indispensable part of the practice of medicine Objective information As a basis for better decisions

Jan 2002 EDMA Economic contribution u Accurate diagnosis u Helps to rule out expensive treatments u Allows procedures and drugs to be targeted u Reduces long term drug treatment u Improves compliance u Reduces costs of treatment of complications u Faster diagnosis u Makes therapy more effective u Containment of disease, lowers risk of infection Avoiding unnecessary treatment Shortening length of hospital stay Investment in in vitro testing provides economic benefits, reducing overall healthcare expenditure

Jan 2002 EDMA Establishing the value of laboratory medicine u Medium to long term benefits of laboratory testing < screening to prevent infection and provide information about risk of disease < early & correct diagnosis ensuring subsequent treatment is relevant and cost-effective < monitoring recovery from trauma and effects of treatment, that allow for reassessment and updating of therapy < objective information supporting Evidence Based Medicine < targeting drug treatments according to patient response In vitro testing is the basis for better decisions in health care